Medicenna Therapeutics to Host a Live Webinar with Q&A to Discuss Updated MDNA11 Clinical Data

Medicenna (OTCQX: MDNAF; TSX: MDNA) will host a live webinar on December 10, 2025 at 08:30 AM ET to discuss updated clinical data from the ABILITY-1 Phase 1/2 study evaluating MDNA11 as a monotherapy and in combination with pembrolizumab.

Rhea-AI Summary

Medicenna (OTCQX: MDNAF; TSX: MDNA) will host a live webinar on December 10, 2025 at 08:30 AM ET to discuss updated clinical data from the ABILITY-1 Phase 1/2 study evaluating MDNA11 as a monotherapy and in combination with pembrolizumab. The event features presentations by company management and the presenting Principal Investigator, followed by commentary from key opinion leaders and live Q&A.

Presenters include Dr. Fahar Merchant (President and CEO), Dr. Arash Yavari (Director of Clinical Strategy) and Dr. André Mansinho (presenting Principal Investigator). Registration is required and a replay will be available on Medicenna’s website after the event.

Argus Dec 10 session

-13.01% close to close Open Argus

Details

News Market Reaction – MDNAF

On Dec 10, the first trading day after this news, MDNAF closed 13.01% below the previous close.

Data tracked by StockTitan Argus for the Dec 10 session.

Key Figures

NEO-CYT centers: up to 12 centres Cash balance: $15.7M Combination ORR: 36% objective response rate +5 more

NEO-CYT centers

up to 12 centres

Planned randomized neoadjuvant NEO-CYT MDNA11 trial in Italy

Cash balance

$15.7M

Reported at Q2 fiscal 2026 with runway into at least mid-2026

Combination ORR

36% objective response rate

MDNA11 plus KEYTRUDA in ABILITY-1 clinical trial

Monotherapy ORR

29.4% objective response rate

MDNA11 monotherapy at ≥60 µg/kg dose in ABILITY-1

Highest ORR subgroup

50% objective response rate

Observed in MSI-H and endometrial cancer patients

Low-dose MDNA11 survival

6/7 mice

Low-dose 2 mg/kg MDNA11 preventing metastasis in TNBC model

High-dose MDNA11 survival

7/8 mice

High-dose 5 mg/kg MDNA11 preventing metastasis in TNBC model

Clinical webinar duration

60 minutes

MDNA11 ABILITY-1 data webinar on December 10, 2025 (08:30–09:30 AM ET)

Historical Context

5 past events · Latest: Nov 13

5 events

1. Nov 13

   Earnings and update

   24h Move

   -2.8%

   Q2 FY26 results plus MDNA11 and MDNA113 pipeline and cash runway update.

2. Nov 06

   Trial collaboration

   24h Move

   -1.9%

   Announcement of NEO-CYT neoadjuvant MDNA11 melanoma trial collaboration in Italy.

3. Oct 23

   Clinical data preview

   24h Move

   +44.7%

   Notice of updated MDNA11 ABILITY-1 clinical data to be presented at ESMO IO.

4. Oct 20

   Conference participation

   24h Move

   +6.7%

   Planned attendance at multiple investor and industry conferences in late 2025.

5. Oct 01

   Conference participation

   24h Move

   -1.7%

   Participation in ROTH healthcare conference with investor meetings on Superkines programs.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

Phase 1/2, pembrolizumab, Principal Investigator, key opinion leaders, +4 more

8 terms

Phase 1/2 medical

"ABILITY-1 Phase 1/2 Study, evaluating MDNA11 as a monotherapy"

Phase 1/2 is a combined early-stage clinical trial that first tests a new drug or treatment for safety and the right dose, then quickly expands to check if it shows any signs of working in patients. For investors, results from a Phase 1/2 study offer an early read on both risk and potential reward—like a prototype test that both confirms a product won’t harm users and suggests whether it could sell—helping guide valuation and development decisions.

pembrolizumab medical

"evaluating MDNA11 as a monotherapy and in combination with pembrolizumab"

A cancer immunotherapy drug that helps the body’s immune system recognize and attack tumor cells by blocking a molecular “brake” that tumors use to hide. Investors watch it because regulatory approvals, clinical trial results, dosing rules, and competition directly affect potential sales, profit forecasts, and the valuation of companies that sell or license the drug—think of trial outcomes as checkpoint signs that can open or close a revenue road.

Principal Investigator medical

"the presenting Principal Investigator along with commentary from key opinion leaders"

A principal investigator is the lead person responsible for overseeing a research project or study, ensuring it stays on track and meets its goals. In the context of investments, this role can be likened to the person in charge of a team or initiative, making key decisions and managing resources. Understanding who the principal investigator is can help investors assess the reliability and credibility of a project or research effort.

key opinion leaders medical

"along with commentary from key opinion leaders to discuss the updated data"

Key opinion leaders are respected experts—often physicians, scientists, or industry specialists—whose published work, clinical experience, or public commentary shapes professional and public views about a medical product, treatment or technology. Investors watch them because their endorsements, criticisms or research can influence regulatory reviews, clinical adoption and sales prospects; think of them as trusted referees whose call can sway public confidence and market demand.

Superkines medical

"development of Superkines for the treatment of cancer as well as autoimmune"

Superkines are engineered versions of natural signaling proteins that have been tuned to work stronger, longer, or with altered targets than the originals. For investors, they matter because these modified proteins can make drug candidates more effective or safer, change how a therapy is dosed, and affect a product’s competitive edge, patent value, and regulatory scrutiny — much like upgrading a standard tool to a more powerful, specialized model.

monotherapy medical

"evaluating MDNA11 as a monotherapy and in combination with pembrolizumab"

Monotherapy is a treatment approach that uses only one type of medicine or therapy to address a condition, instead of combining multiple options. For investors, understanding monotherapy matters because it can influence a company's development strategy, risk profile, and potential market size, especially if the single-treatment approach proves effective or faces limitations compared to combination therapies.

immunotherapy medical

"a clinical-stage immunotherapy company focused on the development of Superkines"

Treatment that uses or enhances the body’s immune system to detect and fight disease, most often cancers or chronic infections; think of it as training or arming the body’s own soldiers to find and destroy targets. It matters to investors because successful immunotherapies can lead to high-value drug approvals, recurring revenue from long-term treatments, and changes in competitive dynamics, while failures or safety issues in clinical trials can materially affect company valuations.

Q&A technical

"Live Webinar with Q&A Registration: Participants can register for the webinar"

Q&A is a live or recorded session in which company leaders or spokespeople answer questions from investors, analysts, or journalists following presentations, earnings calls, or announcements. It matters to investors because the answers reveal management’s priorities, clarify numbers or plans, expose risks or opportunities, and often change market perceptions—similar to asking follow-up questions to judge how confident and consistent someone really is.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

TORONTO and HOUSTON, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines for the treatment of cancer as well as autoimmune and inflammatory diseases is pleased to announce that it will host a live webinar on December 10, 2025 at 08:30 AM Eastern Time.

As previously announced, Medicenna will present updated clinical data from the ABILITY-1 Phase 1/2 Study, evaluating MDNA11 as a monotherapy and in combination with pembrolizumab, on December 10^th at the ESMO Immuno-Oncology Congress 2025. The webinar will have Medicenna’s management team and the presenting Principal Investigator along with commentary from key opinion leaders to discuss the updated data.

Medicenna Therapeutics – KOL Webinar | Live Event Details:

• Date: December 10, 2025
• Time: 08:30 – 09:30 AM ET
• Format: Live Webinar with Q&A
• Registration: Participants can register for the webinar through the link: [Registration]. A replay of the webinar will be available on Medicenna’s website following the event.

The webinar will feature presentations from Medicenna's executive and scientific advisory team, including Dr. Fahar Merchant, President and CEO, Dr. Arash Yavari, Director of Clinical Strategy, and the presenting Principal Investigator Dr. André Mansinho, Assistant Professor, Faculty of Medicine, University of Lisbon. Additional commentary from key opinion leaders and live Q&A will follow the presentation.

About Medicenna Therapeutics

Medicenna is a clinical-stage immunotherapy company focused on developing novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Medicenna’s long-acting IL-2 Superkine, MDNA11, is a next-generation IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Medicenna’s first-in-class targeted PD-1 x IL-2 bispecific, MDNA113, is in development for solid tumors and was designed using the Company’s proprietary BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and T-MASK™ (Targeted Metalloprotease Activated SuperKine) platforms. Medicenna’s IL-4 Empowered Superkine, bizaxofusp (formerly MDNA55), has been studied in 5 clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent GBM, the most common and uniformly fatal form of brain cancer. Bizaxofusp has obtained FastTrack and Orphan Drug status from the FDA and FDA/EMA, respectively.

For more information, please visit www.medicenna.com, and follow us on X and LinkedIn.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, express or implied statements regarding the future operations of the Company, estimates, plans, strategic ambitions, partnership activities and opportunities, objectives, expectations, opinions, forecasts, projections, guidance, outlook or other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expect”, “believe”, “seek”, “potentially” and similar expressions. and are subject to risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the risks detailed in the latest annual information form of the Company and in other filings made by the Company with the applicable securities regulators from time to time in Canada.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date hereof and except as required by law, we do not intend and do not assume any obligation to update or revise publicly any of the included forward-looking statements.

This news release contains hyperlinks to information that is not deemed to be incorporated by reference in this new release.

Investor/Media Contact:

Shushu Feng
Investor Relations, Medicenna Therapeutics
(416) 964-5442
ir@medicenna.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Medicenna hosting the MDNA11 webinar and how long will it last?

The live webinar is on December 10, 2025 from 08:30–09:30 AM ET.

What clinical data will Medicenna discuss in the December 10, 2025 MDNA11 webinar (MDNAF)?

Medicenna will present updated data from the ABILITY-1 Phase 1/2 study evaluating MDNA11 as monotherapy and with pembrolizumab.

Who will present and appear on the Medicenna MDNA11 webinar on December 10, 2025?

Presenters include Dr. Fahar Merchant, Dr. Arash Yavari, and presenting PI Dr. André Mansinho, plus additional key opinion leaders.

How can investors register for the Medicenna (MDNAF) webinar and will a replay be available?

Participants can register through the provided registration link and a replay will be posted on Medicenna’s website after the event.

Will there be an opportunity for live questions during the Medicenna MDNA11 webinar on December 10, 2025?

Yes, the webinar format includes a live Q&A session following the presentations.